Efficacy of Zoster Vaccination in Glioblastoma Patients
ConditionGlioblastoma (GBM)
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Essen
About this trial
In modern practice a trimodality treatment has emerged as standard of care for histologically confirmed glioblastoma.
We hypothesize that the additional vaccination against herpes zoster, after surgical resection followed by irradiation therapy and chemotherapy of patients with glioblastoma will lead to a superior local control, overall and progression free survival. In an additional experimental setting based on patient preference the immunological effectiveness of the adoptive transfer of autologous polyclonal cytomegalovirus (CMV) specific T cells will be examined.
Eligibility criteria
Qualifiers
At least 18 years of age
Written informed consent of the subject
Life expectancy at least 3 months
Participants of child-bearing age must use effective contraception
Disqualifiers
Subjects not able to give consent
Subject without legal capacity who is unable to understand the nature, scope, significance, and con- sequences of this clinical trial
Simultaneously participation in another clinical trial or participation in any clinical trial involving ad- ministration of an investigational medicinal product within 30 days prior to clinical trial beginning
Subjects with a physical or psychiatric condition which at the investigator's discretion may put the subject at risk may confound the trial results or may interfere with the subject's participation in this clinical trial
Trial design
Treatments tested in this trial
- Additional vaccination against shingles (herpes zoster)
- Standard of care treatment without additional vaccination
Treatment groups
230 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
University Hospital, Essen
Lead sponsor
Karolinska Institutet
Collaborator
Leiden University Medical Center
Collaborator
Universitätsklinikum Hamburg-Eppendorf
Collaborator
Source ClinicalTrials.gov